Catalyst Capital Advisors LLC Buys Shares of 363 Insulet Co. (NASDAQ:PODD)

Catalyst Capital Advisors LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 363 shares of the medical instruments supplier’s stock, valued at approximately $95,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PODD. Baillie Gifford & Co. boosted its stake in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after buying an additional 389,639 shares during the last quarter. Mizuho Securities USA LLC boosted its stake in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after buying an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Insulet in the 3rd quarter worth $16,342,000.

Insider Transactions at Insulet

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Price Performance

NASDAQ:PODD opened at $280.71 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business’s 50-day simple moving average is $272.17 and its two-hundred day simple moving average is $245.91. The stock has a market cap of $19.69 billion, a PE ratio of 48.07, a P/E/G ratio of 3.61 and a beta of 1.23. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research reports. Sanford C. Bernstein started coverage on Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $277.13.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.